drugset

Drugs / AGEN2017

Follow last change Feb 2021 re-read 9 days ago

AGEN2017

also known as ASV · AutoSynVax

Developed for: cancer
Investigated by: Agenus Inc.

Trials 1

today NCT03673020 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03673020	May 2019 → Feb 2021	cancer	Agenus Inc.	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2017-04-05	Agenus Inc.	Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™ agenusbio.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AGEN2017	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673020 ↗
Known as	ASV	“This is a Phase 1a study to evaluate neoantigen vaccine, AutoSynVax (ASV®) AGEN2017 in subjects with resected solid tumors, no evidence of disease (NED), and with an estimated...” NCT03673020 ↗
Known as	AutoSynVax	“This is a Phase 1a study to evaluate neoantigen vaccine, AutoSynVax (ASV®) AGEN2017 in subjects with resected solid tumors, no evidence of disease (NED), and with an estimated...” NCT03673020 ↗
Modality	Vaccine	“Neoantigen Vaccine” NCT03673020 ↗
Route	Subcutaneous	“every two weeks subcutaneous injection of AGEN2017 + QS-21 adjuvant” NCT03673020 ↗